Inhibrx Biosciences, Inc.
INBXUnited States
9 filed reports · 206 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
9 reports · Jun 2024 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 7 | 1,087 | Jun 2024 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 2 | 748 | Dec 2024 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 13, 2026 | 272 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 14, 2026 | 147 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 19, 2026 | 469 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 14, 2025 | 213 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 13, 2025 | 120 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 14, 2025 | 120 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 17, 2025 | 279 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 14, 2024 | 135 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 13, 2024 | 80 | Open |
Financial data
206 concepts · 1,835 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial194 concepts · 1,734 facts · Mar 2023 to Jun 2026
- Clinical drug substance and product manufacturing38 · Dec 2023 to Jun 2026
- Clinical trials38 · Dec 2023 to Jun 2026
- Other outside research and development19 · Dec 2023 to Jun 2026
- Outside research and development services19 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value17 · Mar 2023 to Jun 2026
- Interest expense17 · Dec 2023 to Jun 2026
- Net income loss17 · Mar 2023 to Jun 2026
- Stockholders equity (US GAAP)17 · Mar 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents16 · Jun 2023 to Jun 2026
- Depreciation depletion and amortization16 · Jun 2023 to Jun 2026
- General and administrative expense (US GAAP)16 · Jun 2023 to Jun 2026
- Income tax expense benefit16 · Jun 2023 to Jun 2026
- Interest expense nonoperating16 · Jun 2023 to Jun 2026
- Interest income16 · Jun 2023 to Jun 2026
- Nonoperating income expense16 · Jun 2023 to Jun 2026
- Operating expenses (US GAAP)16 · Jun 2023 to Jun 2026
- Operating income loss16 · Jun 2023 to Jun 2026
- Operating lease expense16 · Jun 2023 to Jun 2026
- Other nonoperating income expense16 · Jun 2023 to Jun 2026
- Payments included in measurement of lease liability16 · Jun 2023 to Jun 2026
- Research and development expense16 · Jun 2023 to Jun 2026
- Amortization of financing costs and discounts15 · Sep 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect15 · Sep 2023 to Jun 2026
- Common stock shares issued15 · Dec 2023 to Jun 2026
Segment11 concepts · 78 facts · Dec 2023 to Jun 2026
- Other general and administrative expense11 · Dec 2023 to Jun 2026
- Other research and development expense11 · Dec 2023 to Jun 2026
- Reportable Segment11 · Dec 2023 to Jun 2026
- Net income loss9 · Dec 2023 to Dec 2025
- Other nonoperating income expense8 · Dec 2023 to Sep 2025
- Revenue8 · Dec 2023 to Jun 2026
- Nonoperating income expense6 · Dec 2024 to Jun 2026
- Income tax expense benefit5 · Jun 2024 to Jun 2026
- General and administrative expense (US GAAP)4 · Mar 2025 to Jun 2026
- Segment reporting other item amount3 · Dec 2023 to Dec 2025
- Nonmonetary transaction gain loss recognized on transfer2 · Dec 2024 to Dec 2025
Product1 concepts · 23 facts · Jun 2023 to Jun 2026
- Revenue23 · Jun 2023 to Jun 2026
Segments
101 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 78 facts
- Reportable78 · Dec 2023 to Jun 2026
Product or service2 members · 23 facts
- License13 · Jun 2023 to Jun 2026
- License Non Affiliate10 · Jun 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.